Skip to main content
23.10.2025 | Announcements

Center for Development and Production of Highly Potent Drugs

TZF Polfa, a Polish pharmaceutical manufacturer, proudly presents its latest venture in Warsaw – the Center for Development and Production of Highly Potent Drugs, one of the most advanced injectable drug manufacturing facilities in Europe. This technologically advanced plant fully meets the growing global demand for injectable medicines in various pharmaceutical forms.

The facility covers over 12,000 m², including 3,000 m² of cleanroom areas, and has been designed according to the latest GMP requirements.

At the heart of the Center there are two modern production lines – ONCO and COMBO – that allow the manufacture of drugs across different activity classes (including highly potent) in multiple dosage forms and packaging configurations.

ONCO LINE – Aseptic Filling of Prefilled Syringes and Vials with Solution, Including Lyophilization

The ONCO Line has been designed for handling substances that require the highest level of operational safety. It can process materials with toxicity levels up to OEB 5.

By implementing isolator technology and full robotization, the line ensures maximum operator safety and eliminates the risk of cross-contamination.

The line supports a wide range of packaging materials: vials (2R–50R) and prefilled syringes (0.5–5 ml). Its output capacity ranges from 6 to 10 million units annually, depending on the product and applied technology.

COMBO LINE – Multifunctional Line for Aseptic Filling of Vials with Powders and Solutions, Including Lyophilization

The COMBO Line is a highly flexible aseptic filling system for the production of liquid, powder, and lyophilized drug forms. It operates with a wide range of vial sizes (2R–50R) and is equipped with isolator technology and 100% in-process control, ensuring maximum sterility, automatic inspection, and full GMP compliance.

Its production capacity is around 20 million vials annually.

Both lines cover all stages of sterile production – from raw materials, filling, and closing to individual and collective packaging and quality control – ensuring maximum technical and cost efficiency.

Applied Technologies and Global Standards

The Center boasts its own Research & Development (R&D) department supporting product optimization, modern Quality Control (QC) and stability testing laboratories, and dedicated API and Finished Dosage Form (FDF) storage zones.

It has been designed to meet current EU GMP, FDA, and EAEU regulatory requirements.

  • Compliance with international GMP (EU), FDA, and EAEU standards
  • Full isolator technology ensuring maximum aseptic conditions and operational safety
  • 100% in-process control and automatic inspection systems
  • Fully robotized production line (ONCO Line)
  • Integrated waste management system
ONCO LINE
  • Handles vials (2R, 6R, 10R, 20R, 30R, 50R) and prefilled syringes (0.5 ml, 1 ml, 5 ml), as well as lyophilized forms
  • Designed for handling highly potent substances of up to OEB 5
  • Capacity: close to 6 million units annually
  • Fully automated isolator-based system utilizing single-use components
  • Integrated waste management and in-process control systems
COMBO LINE
  • Handles vial volumes of 2R, 8R, 10R, 30R, and 50R
  • Allows production of liquid, powder, and lyophilized drug forms
  • Capacity: up to 20 million vials annually
  • Isolator-based aseptic technology with complete process control and automatic inspection
  • Rapid changeovers between different pharmaceutical forms
  • Covers all stages of sterile production – from raw materials to final packaging
Laboratory and Support Facilities
  • In-house Research & Development (R&D) department for product optimization and development
  • Quality Control (QC) and stability testing laboratories
  • API and Finished Dosage Form (FDF) storage areas